Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 5/28/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Lloyd Kasper?

Lloyd H. Kasper

Professor of Immunology and Microbiology and Medicine

Geisel School of Medicine at Dartmouth

HQ Phone:  (603) 653-0734

Direct Phone: (866) ***-****direct phone

Email: l***@***.edu

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Geisel School of Medicine at Dartmouth

One Medical Center Drive

Lebanon, New Hampshire,03756

United States

Background Information

Employment History

Director

Dartmouth College


Affiliations

Symbiotix Biotherapies Inc

Co-Founder


Prime Inc

Advisory Board Member


Symbiotix Inc

Co-Founder


Education

M.D.


MD

Dartmouth University


Web References(49 Total References)


Founding Team - Symbiotix Biotherapies, Inc.

symbiotix-bio.com [cached]

Lloyd Kasper, M.D.
Lloyd Kasper, M.D., Professor of Medicine, Microbiology and Immunology, Geisel School of Medicine at Dartmouth College Dr. Lloyd Kasper has been actively involved for many years in basic and applied neuroimmunology supported by research grants from the National Institutes of Health, March of Dimes, National Multiple Sclerosis Society and industry. He has published extensively on the immunology of the obligate intracellular parasite, Toxoplasma gondii, having identified critical antigens and immune pathways that are involved in disease pathogenesis. Some of these parasite antigens have been patented and extensively utilized by industry to develop neonatal screening for toxoplasma infection in the US and Europe. He established and was the long-time Director of the Dartmouth MS Center that serves an MS population of >1500 patients in northern New England. His basic research interests in MS are related primarily to understanding disease pathogenesis, the role of specific regulatory populations elicited by current and novel therapies, and the role of the gut microbiome in the regulation of CNS demyelination. The National Multiple Sclerosis Society (NMSS), NIH and industry have awarded multiple grants to him to support this work. Dr. Kasper has been PI and co-investigator for NIH supported clinical trials in MS including anti-CD40L (CD154), CombiRx, estriol plus glatiramer and CTLA4-Ig. He has served as an advisor for industry (Biogen Idec, Novartis, Genzyme, Sanofi, Teva Neuroscience, Mederex, Centocor, Bayer Healthcare, EMD Serono, ONO Pharmaceuticals, Genentech) on clinical and research protocol development for a number of clinical trials in MS including rituximab, ocrilizumab, alumtuzumab, daclizumab, ONO-4641, anti-IL12p40, lacquinimod, anti-CD40, CTLA-4Ig, TACI-Ig, and FTY-720. He has served in ad hoc, permanent and chairperson positions on NIH and NMSS study section. He has organized three Keystone symposia including Opportunistic Infections in AIDS, Translational Medicine in Autoimmunity and most recently the Role of the Gut Microbiome: Effector/Regulatory Networks that was held in February 2013. Dr. Kasper has authored over 175 research and clinical articles related to his basic research interests in immunology and clinical expertise in multiple sclerosis.


Scientific Advisory Board – Symbiotix Biotherapies, Inc.

symbiotix-bio.com [cached]

Lloyd Kasper, M.D. - Founder and Director
Professor of Medicine, Microbiology and Immunology, Geisel School of Medicine at Dartmouth College


Founding Team – Symbiotix Biotherapies, Inc.

symbiotix-bio.com [cached]

Lloyd Kasper, M.D.
Lloyd Kasper, M.D., Professor of Medicine, Microbiology and Immunology, Geisel School of Medicine at Dartmouth College Dr. Lloyd Kasper has been actively involved for many years in basic and applied neuroimmunology supported by research grants from the National Institutes of Health, March of Dimes, National Multiple Sclerosis Society and industry. He has published extensively on the immunology of the obligate intracellular parasite, Toxoplasma gondii, having identified critical antigens and immune pathways that are involved in disease pathogenesis. Some of these parasite antigens have been patented and extensively utilized by industry to develop neonatal screening for toxoplasma infection in the US and Europe. He established and was the long-time Director of the Dartmouth MS Center that serves an MS population of >1500 patients in northern New England. His basic research interests in MS are related primarily to understanding disease pathogenesis, the role of specific regulatory populations elicited by current and novel therapies, and the role of the gut microbiome in the regulation of CNS demyelination. The National Multiple Sclerosis Society (NMSS), NIH and industry have awarded multiple grants to him to support this work. Dr. Kasper has been PI and co-investigator for NIH supported clinical trials in MS including anti-CD40L (CD154), CombiRx, estriol plus glatiramer and CTLA4-Ig. He has served as an advisor for industry (Biogen Idec, Novartis, Genzyme, Sanofi, Teva Neuroscience, Mederex, Centocor, Bayer Healthcare, EMD Serono, ONO Pharmaceuticals, Genentech) on clinical and research protocol development for a number of clinical trials in MS including rituximab, ocrilizumab, alumtuzumab, daclizumab, ONO-4641, anti-IL12p40, lacquinimod, anti-CD40, CTLA-4Ig, TACI-Ig, and FTY-720. He has served in ad hoc, permanent and chairperson positions on NIH and NMSS study section. He has organized three Keystone symposia including Opportunistic Infections in AIDS, Translational Medicine in Autoimmunity and most recently the Role of the Gut Microbiome: Effector/Regulatory Networks that was held in February 2013. Dr. Kasper has authored over 175 research and clinical articles related to his basic research interests in immunology and clinical expertise in multiple sclerosis.


CMSC INforMS: #CMSC16 - Lifestyle Factors and Unconventional Medicine in MS Care - Consortium of Multiple Sclerosis Centers (CMSC)

www.mscare.org [cached]

Dr. Lloyd Kasper, professor of medicine and microbiology/immunology at the Geisel School of Medicine at Dartmouth, was the final speaker of the symposium, and he presented a talk titled "You Are What You Eat - The Role of the Gut Microbiome in CNS Disease."
He began by explaining that "we start with a mostly sterile gut," with infants and babies having a low gut microbial diversity. "Between 1 and 3 years of age, our gut microbial communities become progressively more diverse, [and] continue to develop as we eat more solid foods and explore the world around us." "By adulthood the gut microbiome is a highly complex ecosystem containing bacteria, virus, and fungi that are symbiotic with the host," Kasper continued, then "as we age there is progressive loss of the stability that we had as younger adults." He said diet has a strong impact on the composition of the gut microbiota. This can lead to changes in intestinal permeability - what is called a "leaky gut," and also changes in the immune system, promoting, for instance, pro-inflammatory responses. A correct balance in the gut microbiota is necessary for a healthy state. Kasper showed that germ-free mice (with no or reduced gut microbiota) had a reduced disease severity of experimental autoimmune encephalomyelitis (EAE), a condition in mice mimicking human MS. These animals also had reduced levels of IL-17 and gamma interferon, which are associated with a pro-inflammatory state.


2014 Annual Meeting | Clinical Immunology Society

www.clinimmsoc.org [cached]

Lloyd Kasper, MD
Geisel School of Medicine at Dartmouth


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory